Afinitor Disperz Patent Expiration

AFINITOR DISPERZ's oppositions filed in EPO
Can you believe AFINITOR DISPERZ received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6004973 NOVARTIS PHARM Pharmaceutical compositions comprising rafamycin coprecipitates
Jul, 2016

(8 years ago)

US6004973

(Pediatric)

NOVARTIS PHARM Pharmaceutical compositions comprising rafamycin coprecipitates
Jan, 2017

(7 years ago)

US5665772 NOVARTIS PHARM O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Sep, 2019

(4 years ago)

US7297703 NOVARTIS PHARM Macrolides
Dec, 2019

(4 years ago)

US5665772

(Pediatric)

NOVARTIS PHARM O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Mar, 2020

(4 years ago)

US7297703

(Pediatric)

NOVARTIS PHARM Macrolides
Jun, 2020

(4 years ago)

US8778962 NOVARTIS PHARM Treatment of solid tumors with rapamycin derivatives
Feb, 2022

(2 years ago)

US8778962

(Pediatric)

NOVARTIS PHARM Treatment of solid tumors with rapamycin derivatives
Aug, 2022

(1 year, 10 months ago)

US8617598 NOVARTIS PHARM Pharmaceutical compositions comprising colloidal silicon dioxide
Sep, 2022

(1 year, 9 months ago)

US8617598

(Pediatric)

NOVARTIS PHARM Pharmaceutical compositions comprising colloidal silicon dioxide
Mar, 2023

(1 year, 3 months ago)



Afinitor Disperz is a drug owned by Novartis Pharmaceutical Corp. It is used for managing partial-onset seizures associated with Tuberous Sclerosis Complex. Afinitor Disperz uses Everolimus as an active ingredient. Afinitor Disperz was launched by Novartis Pharm in 2012. It is is available in tablet, for suspension form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 10, 2025 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-630) Oct 29, 2013
New Chemical Entity Exclusivity(NCE) Mar 30, 2014
Pediatric Exclusivity(PED) Apr 29, 2018
Orphan Drug Exclusivity(ODE) Oct 29, 2017
New Indication(I-773) Apr 10, 2021
Orphan Drug Exclusivity(ODE-169) Apr 10, 2025

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using EVEROLIMUS ingredient

NCE-1 date: 29 April, 2017

Market Authorisation Date: 29 August, 2012

Treatment: Adjunctive treatment of patients with tsc-associated partial-onset seizures

Dosage: TABLET, FOR SUSPENSION

How can I launch a generic of AFINITOR DISPERZ before it's drug patent expiration?
More Information on Dosage

AFINITOR DISPERZ family patents

Family Patents